Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients

Hui Peng, Li-tao Yang, Ling-yun Wang, Jian Li, Jun Huang, Zhi-qiang Lu, Richard A Koup, Robert T Bailer, Chang-you Wu, Hui Peng, Li-tao Yang, Ling-yun Wang, Jian Li, Jun Huang, Zhi-qiang Lu, Richard A Koup, Robert T Bailer, Chang-you Wu

Abstract

The nucleocapsid (N) protein is a structural component of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) and can induce antibody responses in SARS patients during infection. However, it is not known whether SARS-CoV N protein can induce a long persistence of memory T-cell response in human. In this study, we found that peripheral blood mononuclear cells (PBMCs) from fully recovered SARS individuals rapidly produced IFN-gamma and IL-2 following stimulation with a pool of overlapping peptides that cover the entire N protein sequence. The N-specific IFN-gamma(+)CD4(+) T cells were mainly composed of CD45RA(-)CCR7(+)CD62L(-) cells, whereas IFN-gamma(+)CD8(+) memory T cells were mostly contained within CD45RA(+)CCR7(-)CD62L(-) cell population. Epitope mapping study indicated that a cluster of overlapping peptides located in the C-terminal region (amino acids [aa] 331 to 362) of N protein contained at least two different T-cell epitopes. The results indicated that human memory T-cell responses specific for SARS-CoV N protein could persist for 2 years in the absence of antigen, which would be a valuable for the design of effective vaccines against SARS-CoV and for basic studies of human T-cell memory.

Figures

Fig. 1
Fig. 1
Production of IFN-γ by PBMCs from SARS-recovered individuals induced with a pool of SARS-CoV N peptides. (A) PBMCs from seven SARS-recovered donors were cultured in 96-well plates with or without a pool of N peptides for 72 h. The culture supernatants were collected and assessed for the production of IFN-γ by ELISA. All of assays were performed in triplicate. Statistical analysis used a Student's t test. Statistical significant difference was set at P < 0.05(**). *P > 0.05. Bars indicate mean values. (B) PBMCs from eleven SARS-recovered donors were stimulated with a pool of N peptides. IFN-γ-producing cells were detected by ELIspot assay. PBMCs incubated with medium alone were used as negative controls. The number of spots in the medium control wells ranged from 0 to 2. All of assays were performed in triplicate. Statistical analysis used a Student's t test. Statistical significant difference was set at P < 0.05(**). *P > 0.05. Bars represent mean values.
Fig. 2
Fig. 2
Detection of IFN-γ-producing T cells specific to SARS-CoV N peptides by intracellular staining. PBMCs from SARS-recovered donors were incubated with a pool of peptides for 6 h. Cell surface and intracellular cytokine staining for IFN-γ was performed. The cells were first gated on CD4−CD8+ T cells (A) and CD8−CD4+ T cells (B) and analyzed for IFN-γ expression. Results shown are from one experiment performed on PBMC from a SARS patient and are representative of 5 independent experiments from 5 SARS patients. C represents the expression of IFN-γ as percentage of total CD4+ or CD8+ T cells in different patients. Bars indicate mean values.
Fig. 3
Fig. 3
Cytokine profiles of IL-2 and IFN-γ in CD4+ and CD8+ T cells in response to N peptides. PBMCs from SARS-recovered donors were stimulated with a pool of N peptides for 6 h. The expression of IL-2 and IFN-γ was assessed by flow cytometry. (A) Dot plots show intracellular staining for IL-2 and IFN-γ in the CD8+ T cells and CD4+ T cells. Data are representative of three independent experiments with similar results. (B) The frequency of cells expressing both IL-2 and IFN-γ in PBMCs from SARS-recovered donors. Data are presented as the percentage of the total number of cells expressing at least one cytokine.
Fig. 4
Fig. 4
Determination of phenotype of N-protein-specific memory T cells in SARS-recovered donors. PBMCs from SARS-recovered donors were stimulated with a pool of N peptides for 6 h. The expression of CD45RA, CCR7 and CD62L in IFN-γ+CD4+ or IFN-γ+CD8+ T cells was assessed by flow cytometry. CD4 +CD8− or CD4 +CD8− cells were gated and analyzed. Results shown are from one experiment performed on PBMC from a SARS patient and are representative of 3 independent experiments from 3 SARS patients.
Fig. 5
Fig. 5
Specific T-cell responses to pooled peptides of the N protein in SARS-recovered donors by ELISA and ELIspot assay. Fifty seven overlapping individual peptides that covered the entire N protein sequence were divided into 6 pools (each pool contains 10 peptides) as described in Materials and methods. (A) PBMCs from 5 SARS-recovered donors were stimulated with a pool of 10 peptides (1 μg/ml of each peptide) for 72 h. The culture supernatants were collected for detection of IFN-γ by ELISA. Bars indicate mean values. (B) PBMCs from four SARS-recovered donors were stimulated with a pool of 10 peptides (1 μg/ml of each peptide) for detection of IFN-γ expression by ELIspot assay. PBMCs incubated with media alone were used as negative controls. The experiments were carried out in triplicate.
Fig. 6
Fig. 6
T-cell responses to individual peptide of SARS-CoV N protein by ELIspot assay. PBMCs from SARS-recovered donors were stimulated with a single peptide (1 μg/ml). The production of IFN-γ was assessed by ELIspot assay. The number of spots in the media control wells was ranged from 0 to 2. The experiments were carried out in triplicate.
Fig. 7
Fig. 7
Memory T-cell responses specific to the peptides N46, N47 or N48 by intracellular staining. PBMCs from SARS-recovered donors were incubated with the indicated peptides (N46, N47 or N48) for 6 h. The intracellular staining for IFN-γ was performed. CD4+ and CD8+ T cells were gated and analyzed for IFN-γ expression by flow cytometry (A). Results shown are representative of 3 independent experiments from 3 SARS patients. Similar results were also obtained in other experiments for CD8+ (B) and CD4+ (C) T cells.

References

    1. Boots A.M., Benaissa-Trouw B.J., Hesselink W., Rijke E., Schrier C., Hensen E.J. Induction of anti-viral immune responses by immunization with recombinant-DNA encoded avian coronavirus nucleocapsid protein. Vaccine. 1992;10:119–124.
    1. Chen Z., Pei D., Jiang L., Song Y., Wang J., Wang H., Zhou D., Zhai J., Du Z., Li B., Qiu M., Han Y., Guo Z., Yang R. Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein. Clin. Chem. 2004;50:988–995.
    1. Collisson E.W., Pei J., Dzielawa J., Seo S.H. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev. Comp. Immunol. 2000;24:187–200.
    1. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A.M., Berger A., Burguière A.-M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.-C., Müller S., Rickerts V., Stürmer M., Klenk S.H.D., Osterhaus A.D.M.E., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967–1976.
    1. Falsey A.R., Walsh E.E. Novel coronavirus and severe acute respiratory syndrome. Lancet. 2003;361:1312–1313.
    1. Gao W., Tamin A., Soloff A., Aiuto L.D, Nwanegbo E., Robbins P.D., Bellini W.J., Barratt-Boyes S., Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362:1895–1896.
    1. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 2003;9:1131–1137.
    1. Harari A., Vallelian F., Meylan P.R., Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 2005;174:1037–1045.
    1. He Y., Zhou Y., Wu H., Kou Z., Liu S., Jiang S. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 2004;42:5014–5309.
    1. Hiscox J.A., Wurm T., Wison L., Britton P., Cavanagh D., Brooks G. The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus. J. Virol. 2001;201:506–512.
    1. Hoey J. Updated SARS case definition using laboratory criteria. CMAJ. 2003;168:1566–1567.
    1. Hoffmeister B., Kiecker F., Tesfa L., Volk H.D., Picker L.J., Kern F. Mapping T cell epitopes by flow cytometry. Methods. 2003;292:270–281.
    1. Huang J.L., Huang J., Duan Z.H., Wei J., Min J., Luo X.H., Li J.G., Tan W.P., Wu L.Z., Liu R.Y., Li Y., Shao J., Huang B.J., Zeng Y.X., Huang W.L. Th2 predominance and CD8+ memory T cell depletion in patients with severe acute respiratory syndrome. Microbes Infect. 2005;7:427–436.
    1. Jameson J., Cruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998;72:8682–8689.
    1. Jin K., Chong X., Chen Z., Chen Z., Kang Y., Ma Y., Zhu K., Xie Q., Tu Y., Yua Y., Wang B. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem. Biophys. Res. Commun. 2005;328:979–986.
    1. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., Viscidi R., Tsai Y.C., He L., Chen P.J., Boyd D.A., Wu T.C. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 2004;78:4638–4645.
    1. Lalvani A., Brookes R.S., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 1997;186:859–865.
    1. Lau L.L., Jamieson B.D., Somasundaram T., Ahmed R. Cytotoxic T-cell memory without antigen. Nature. 1994;369:648–652.
    1. Li G., Chen X., Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med. 2003;349:508–509.
    1. Liang Y., Wan Y., Qiu L., Zhou J., Ni B., Guo B., Zou Q., Zou L., Zhou W., Jia Z., Che X., Wu Y. Comprehensive antibody epitope mapping of the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus: insight into the humoral immunity of SARS. Clin. Chem. 2005;51:1382–1396.
    1. Lier R.A.W., Berge I.J.M., Gamadia L.E. Human CD8+ T-cell differentiation in response to viruses. Nat. Rev., Immunol. 2003;3:1–8.
    1. Lin Y., Shen X., Yang R.F., Li Y.X., Ji Y.Y., He Y.Y., Shi M.D., Lu W., Shi T.L., Wang J., Wang H.X., Jiang H.L., Shen J.H., Xie Y.H., Wang Y., Pei G., Shen B.F., Wu J.R., Sun B. Identification of an epitope of SARS-coronavirus nucleocapsid protein. Cell Res. 2003;13:141–145.
    1. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L. The genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404.
    1. Mo H.Y., Xu J., Ren X.L., Zeng G.Q., Tan Y.X., Chen R.C., Moira C.Y., Zhong N.S. Evaluation by indirect immunofluorescent assay and enzyme linked immunosorbent assay of the dynamic changes of serum antibody responses against severe acute respiratory syndrome coronavirus. Chin. Med. J. 2005;118:150–446.
    1. Murali-Krishna K., Lau L.L., Sambhara S., Lemonnier F., Altman J., Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 1999;286:1377–1381.
    1. Narayanan K., Chen C.J., Maeda J., Makino S. Nucleocapsid-independent specific viral RNA packaging via viral envelope protein and viral RNA signal. J. Virol. 2003;77:2922–2927.
    1. Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L., Lim W., Nicholls J., Yee W., Yan W., Cheung M., Cheng V., Chan K., Tsang D., Yung R., Ng T., Yuen K. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.
    1. Sallusto F., Lenig D., Forster R., Lipp M., Anzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–712.
    1. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Rev., Immunol. 2003;9:835–842.
    1. Stohlman S.A., Bergmann C., Cua D., Wege H., van der Veen R. Location of antibody epitopes within the mouse hepatitis virus nucleocapsid protein. Virology. 1994;202:146–153.
    1. Stohlman S.., Bergmann C.C., Roel D., van der Veen R.C., Hinton D.R. Mouse hepatitis virus nucleocapsid-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system. J. Virol. 1995;69:684–694.
    1. Tan Y.J., Lim S.J., Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antivir. Res. 2004;65:69–78.
    1. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., Lam W.K., Seto W.H., Yam L.Y., Cheung T.M., Wong P.C., Lam B., Ip M.S., Chan J., Yuen K.Y., Lai K.N. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003;348:1977–1985.
    1. Wesseling J.G., Godeke G.J., Schijns V.E., Prevec L., Graham F.L., Horzinek M.C., Rottier P.J. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J. Gen. Virol. 1993;74:2061–2069.
    1. Wherry E., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 2004;78:5535–5545.
    1. Wills M.R., Okecha G., Weekes M.P., Gandhi M.K., Sissons P.J.G., Carmichael A.J. Identification of naive or antigen-experienced human CD8+ T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8+ T cell response. J. Immunol. 2002;168:5455–5464.
    1. Wu Z.D., Wu D., Zhen H.Q, Xu J., Yu X.B. Epidemiological analysis on SARS infection of clinical practice. Zhong guo gong gong wei shen. 2004;20:32–34.
    1. Xu D., Zhang Z., Jin L., Chu F., Mao Y., Wang H., Liu M., Wang M., Zhang L., Gao G.F., Wang F.S. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur. J. Clin. Microbiol. Infect. Dis. 2005;24:165–171.
    1. Zhao P., Cao J., Zhao L.J., Qin Z.L., Ke J.S., Pan W., Ren H., Yu J.G., Qi Z.T. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology. 2005;331:128–135.
    1. Zhong X., Yang H., Guo Z.F., Sin W.Y.F., Chen W., Xu J., Fu L., Wu J., Mak C.K.G., Cheng C.S.S., Yang Y., Cao S., Wong T.Y., Lai S.T., Xie Y., Guo Z. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J. Virol. 2005;79:3401–3408.
    1. Zhu M.S., Pan Y., Chen H.Q., Shen Y., Wang X.C., Sun Y.J., Tao K.H. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol. Lett. 2004;92:237–243.

Source: PubMed

3
Abonnere